Lurasidone-Fluvoxamine Combination: Critical Drug Interaction Warning

Primary Pharmacokinetic Concern

• Lurasidone is metabolized primarily through CYP3A4, and fluvoxamine is a potent inhibitor of CYP3A4, which will dramatically increase lurasidone plasma levels and risk of extrapyramidal symptoms, akathisia, and somnolence 1

Additional Safety Concerns in Bipolar Disorder

• SSRIs should be avoided in men with a history of bipolar depression due to risk of mania, and when used, should only be adjuncts when patients are taking at least one mood stabilizer 2, 3, 4

Serotonin Syndrome Risk

• Serotonin syndrome is a potentially serious complication most often associated with simultaneous use of multiple serotonergic drugs, presenting with clonus, tremor, hyperreflexia, agitation, mental status changes, diaphoresis, and fever 2, 3
• Severe cases may be associated with seizure and rhabdomyolysis, requiring cessation of serotonergic agents and benzodiazepines for symptom management 2, 3

Critical Clinical Pitfalls to Avoid

• Do not use SSRIs as monotherapy in bipolar disorder—they require concurrent mood stabilizer therapy and carry mania induction risk 2, 3, 4
• Monitor for early signs of serotonin syndrome when any serotonergic combinations are unavoidable, though this specific combination should be avoided entirely 2, 3